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For treatment of advanced heart failure, current strategies 
include cardiac transplantation or blood-contacting pump 
technology associated with complications, including stroke 
and bleeding. This study investigated an individualized biven-
tricular epicardial augmentation technology in a drug-induced 
porcine failing heart model. A total of 11 pigs were used, for 
the assessment of hemodynamics and cardiac function under 
various conditions of support pressures and support durations 
(n = 4), to assess device positioning and function by in vivo 
computer tomographic imaging (n = 3) and to investigate a 
minimally invasive implantation on the beating heart (n = 4). 
Support pressures of 20–80 mm Hg gradually augmented car-
diac function parameters in this animal model as indicated 
by increased left ventricular stroke volume, end-systolic pres-
sures, and decreased end-diastolic pressures. Strong evidence 
was found regarding the necessity of mechanical synchroniza-
tion of support end with the isovolumetric relaxation phase 
of the heart. In addition, the customized, self-expandable 
implant enabled a marker-guided minimally invasive implan-
tation through a 4 cm skin incision using fluoroscopy. Correct 
positioning was confirmed in computer tomographic images. 
Continued long-term survival investigations will deliver pre-
clinical evidence for further development of this concept. 
ASAIO Journal 2018; 64:480–488.
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To date, many attempts have been made to improve the 
outcome of patients with implanted ventricular assist devices 
(VADs) in order to establish a true alternative to heart trans-
plantation. Pruijsten et al. reported an extensive hemodynamic 
recovery compatible with daily life activities in left ventricular 
(LV) assist device (LVAD) patients. They suggested that improved 
survival with newer generation devices will provide an alterna-
tive to heart transplantation in selected patients.1 Current VAD 
technology is associated with a high rate of complications, 
rehospitalization, and cost.2 Even though improvements have 
been made regarding adverse event rate and survival, a high 
rate of patients experience at least one major complication 
within 12 months after implantation.3,4
Recent efforts focus on the development of less complex, 
minimally invasive strategies for mechanical cardiac support. 
One key strategy is to avoid blood contact as the major driver 
for complications such as stroke and bleeding. Some extra-
vascular devices were intended to compressing the ventricles 
of the heart using pneumatic or hydraulic expandable units 
positioned inside the pericardial space.5–8 These devices were 
mainly investigated in the scope of acute heart failure (HF) ani-
mal models. However, promising results have clearly shown the 
potential of this technology in five human patients with cardio-
genic shock.9 It may also serve as an adjunctive, less complex 
therapeutic approach to established blood-contacting impeller 
pumps that are currently used to treat advanced HF patients.
In the current study, we investigated a novel biventricu-
lar epicardial augmentation technology (AdjuCor GmbH, 
Munich, Germany) in an acute, drug-induced porcine failing 
heart model. The technology specifically addresses require-
ments for potential clinical use: 1) customized, patient-specific 
configuration of the implant to allow unconstrained diastolic 
relaxation and filling; 2) reliable and exact synchronization to 
each cardiac cycle as a mandatory prerequisite for the augmen-
tation of cardiac hemodynamics; 3) uni- and biventricular sup-
port with adjustable subsystemic pressure ranges for gradual 
augmentation of impaired cardiac function parameters; and 4) 
self-expandable material for a minimally invasive implantation 
on the beating heart.
Methods
The investigation conforms to the “Guide for the Care and 
Use of Laboratory Animals” published by the US National 
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Institutes of Health (NIH Publication No. 85-23, revised 1985). 
The experimental protocol was approved by the institutional 
“Animal Care and Use Committee” of the University of Ulm, 
Germany, and the legal authority of the State of Baden-Würt-
temberg, Germany, and the institutional “Animal Care and Use 
Committee” of the State of Bavaria, Munich, Germany.
Eleven pigs of either gender with a median (interquartile 
range) body weight of 83 (70–86) kg were used to study device 
function in vivo: Four pigs were used for catheter-based assess-
ment of cardiac function parameters. Three pigs were used for 
computer tomographic (CT) imaging of anatomic fit and device 
function. Four pigs were used for evaluation of a closed-chest 
interventional device implantation. After the experiments, ani-
mals were sacrificed under deep anaesthesia.
Individualized Implant Development, Design, and Production
The implant manufacturing process is based on a CT scan 
of each individual pig heart before the experiment day. It was 
triggered to the time point of maximum diastolic filling. The CT 
images were used to segment the ventricular portion of the heart 
from the apex to the valve plane using MIMICS software (Materi-
alise, Leuven, Belgium; Figure 1A). Based on the resulting virtual 
and real three-dimensional (3D) models of the pig’s heart (Fig-
ure 1, B and C), an offset nitinol sheath and a fitting polyurethane 
sleeve resembling the shape of the ventricles were manufactured 
(Figure 1D) and bonded (Figure 1E). Three inflatable pneumatic 
units were positioned to the inside of the implant according to 
anatomically predefined locations of each individual animal, two 
facing opposite sides of the LV and one facing the right ventricle 
(RV). They were tested to withstand millions of inflation cycles 
within the given pressure range of 20–80 mm Hg.
Electropneumatic Control Unit
The electrocardiogram (ECG) was used as a physiological 
input signal for the pneumatic control unit. It was sensed through 
an endocardially placed electrode, connected to an integrated 
electronic control circuit in the driving unit. During support, all 
pneumatic units were inflated immediately after R-wave detec-
tion by opening electronically controlled solenoid valves. The 
valves were regulated by a proportional integral differential con-
troller for precise support pressure control. The necessary supply 
pressure was created by a brushless motor in a closed pressure 
reservoir and transmitted by three different tubes, leading to the 
pneumatic support units on the epicardium. Controlled active 
deflation of the support units during diastole was achieved by 
connecting the supply tubes to a closed low-pressure reservoir. 
This was done by opening three separate solenoid valves.
Support started during the isovolumetric contraction phase 
of the heart (Figure 2). Support duration tSD was adjusted for 
variations in heart rate (HR) in each cardiac cycle via a linear 
approximation of Bazett’s and Fridericia’s formula10:
 t tSD offsetms/bpm HR= − ⋅ +2  (1)
toffset was taken from the ECG and LV–pressure curves individu-
ally for each pig such that the pneumatic units were deflated 
during isovolumetric relaxation phase (Figure 2). To assess the 
effects of support duration on cardiac function parameters, 
tSD was varied between 80% and 110% of the actual systolic 
length Tsys during a subset of measurements.
Anaesthesia and Open-Chest Implantation
After premedication, anaesthesia was induced with propo-
fol (1–2 mg/kg) and S-ketamine (0.5–1.0 mg/kg). After endotra-
cheal intubation, anaesthesia, analgesia, and muscle relaxation 
were achieved with continuous pentobarbitone (8 mg/[kg h]), 
pancuronium (0.1 mg/[kg∙h]), and intermittent buprenorphine 
(20–30 µg/kg) before painful stimuli. A central-venous cath-
eter, an arterial catheter, a fast response pulmonary artery 
catheter (CCOmbo; Edwards Lifesciences, Irvine, CA) and a LV 
pressure–conductance (PV) catheter were placed via the neck 
Figure 1. Patient-specific device manufacture: after segmentation of computer tomography (CT) data (A), three-dimensional (3D) surface 
rendering technique is used to create virtual 3D geometries (B). This is followed by the production of patient-specific implant forms (C), which 
serve as molds for the implant’s components (D). These are assembled and connected to the pneumatic tubes (E). 
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vessels for drug infusions, blood sampling, and continuous 
measurement of mean arterial pressure, mixed-venous hemo-
globin oxygen saturation, RV end-diastolic volume, ejection 
fraction (EF), and LV end-systolic and end-diastolic pressures 
(LVESP and LVEDP). A transpulmonary thermodilution cath-
eter (PiCCO) was placed via the femoral artery to continuously 
measure cardiac output (CO) and stroke volume (SV).
For the functional assessments, implantation was performed 
via a lower partial sternotomy and partial pericardiotomy 
( Figure 3, A and B). The customized implants were positioned 
on the beating heart via the apex respecting the animals’ anat-
omy such that the pneumatic units were positioned accord-
ing to the predefined locations (Figure 3C). Customization 
of the implants significantly facilitated the implantation by 
Figure 2. The QRS complex of the electrocardiogram (ECG) is used as the trigger for support synchronization to each cardiac cycle by 
the electropneumatic driver. Individual support pressures for left and right ventricle as well as support duration may be freely adjusted. An 
example of support pressure of 40 mm Hg with its duration equal to the systolic length is shown. 
Figure 3. Implantation and positioning: stable device positioning was achieved after lower partial sternotomy and pericardiotomy (A). 
Correct anterior-posterior orientation of the device was mandatory to achieve unrestricted filling of the heart during diastole (B and C). The 
chest was closed for all functional experiments (D). Pressure–volume (PV) loops before and after device implantation showed no signs for left 
ventricular restriction by the device (E). 
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self-positioning/orientation during the first few beats. The chest 
remained closed throughout the measurements (Figure 3D)
Catheter-Based Measurements (n = 4)
Normal cardiac function was assessed with and without the 
implant to account for restrictions of diastolic relaxation and 
filling. The heart in normal state was not actuated. The hemo-
dynamic state of an acute HF was then induced by β1-blockade 
with 1 mg/kg bolus esmolol followed by a continuous infusion 
at 170 μg/(kg∙min) and doubling of the pentobarbitone dose. 
Once hemodynamic parameters were stable, changes of car-
diac function parameters from baseline values were assessed 
with respect to LV and RV support pressures and variations in 
support duration (Figure 2). Data were always collected for 
30 s, 5 to 10 min after the start of epicardial support.
In Vivo Device Imaging (n = 3)
In three animals, anatomic fit and positioning of the implant 
and visualization of biventricular assist device (BiVAD), LVAD, 
and RV assist device (RVAD) support were assessed. Further-
more, LV stroke volume (LVSV) changes and EF of the LV and 
RV were measured by a team of two radiologists and two 
experienced professionals who performed CT volumetry using 
Simpson’s method.
Afterwards, asystole was induced in pentobarbitone anaes-
thesia with potassium chloride to study a fixed-frequency 
BiVAD support mode for the duration of 30 min.
Closed-Chest Implantation (n = 4)
Using four animals, we developed a closed-chest implanta-
tion technique. Through a 4–5 cm median subxyphoideal skin 
incision, the pericardium was opened. The self-expandable 
implants were radially crimped down to 30 mm (Figure 4A) 
in cold saline and inserted into the chest (Figure 4B). A safe 
and straightforward expansion of the implant into the pericar-
dial space was achieved under fluoroscopic control (Figure 4, 
D–F). Care was taken to respect the anterior–posterior orien-
tation. We observed a final self-alignment in circumferential 
direction. Correct positioning was confirmed within the intact 
pericardium after partial sternotomy (Figure 4G).
Statistical Evaluation
Data are presented as median (interquartile range) unless 
otherwise stated. Hemodynamic changes during support were 
assessed using a linear fixed-effects model.11 This regression-
based statistical model was preferred more than traditional 
statistical tests such as analysis of variance as it is more robust 
when dealing with missing measurements and a lack in preci-
sion of the control variables. The following equation was fitted 
to the data set to analyze whether LV support pressure PLV, RV 
support pressure PRV, and support duration D, respectively, had 
a significant influence on cardiac function parameter changes:
 Y c P c P c D e= + + +× × ×1 2 3LV RV  (2)
with Y being LVSV, LVESP, or LVEDP, respectively, and e the 
remaining error term.
The coefficient estimates cj, j = 1,2,3 were calculated from a 
multiple regression analysis through the origin, using a maxi-
mum pseudo likelihood fit of the model to the data set. Their 
value is the slope of the linear dependency between control 
variable and cardiac function parameter. They were tested for 
statistically significant difference from 0—corresponding to “no 
dependence on this variable”—using t-statistic tests. The residu-
als were analyzed for normal distribution with mean equal to 
zero to ensure that the data was well described by the model.
Figure 4. Closed chest minimally invasive device implantation. The implant was crimped to a diameter of 30 mm after cooling (A). The 
crimped implant was brought through the opened pericardium via a small sub-xyphoideal incision (median axis of the heart in pigs; B) before 
skin closure (C). Thereafter, circumferential expansion while the implant was ascending around the beating heart was controlled via fluoros-
copy (D–F). Inspection of the in situ device position with sternotomy and intact pericardium (G). 
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Results
In all 11 animals, customized implants were successfully posi-
tioned around the heart through a partial lower sternotomy or sub-
xyphoideal closed-chest approach. In most animals, we observed 
some manipulation-induced arrhythmias during implantation 
without hemodynamic instability. However, after implantation, 
all animals were found in stable sinus rhythm (Table 1).
Catheter-Based Measurements
Figure 3E shows changes in a representative PV loop, 
observed after device implantation and reduction in HR. 
Unrestricted LV function, especially end-diastolic filling, was 
preserved. In addition, CT images revealed no signs of com-
promised ventricular filling (Figure 7A).
Changes of cardiac function parameters with respect to sup-
port duration tSD and support pressures PLV and PRV in the func-
tional HF state are shown in Figures 5 and 6. Figure 5A shows 
an early stop of support (arrow at 90% systole length) during 
systole, which causes an immediate drop in LV pressure. In 
Figure 5B, support duration was set to the length of the systole 
(100%), resulting in an undisturbed morphology of the ventric-
ular pressure curve. Prolonging the support duration towards 
the early diastolic filling phase (110%) as shown in Figure 5C 
leads to an extended isovolumetric relaxation period.
Changes in LVEDP, LVESP, and LVSV during BiVAD, LVAD, 
and isolated RV (RVAD) support for different support pressures 
are shown in Figure 6A. All values were calculated as differ-
ences to their individual baseline without support. All support 
modes elevated LVESP and LVSV proportional to the increasing 
support pressure. However, although BiVAD and LVAD sup-
port decreased LVEDP, it was increased during RVAD support. 
The LV pressure curves during BiVAD support are shown in 
Figure 6B.
Figure 6C summarizes the results of the statistical analysis 
of the complete data set. Statistically significant dependencies 
with p < 0.05 were found with increasing LV or RV support 
pressures and when prolonging support duration from 80% 
systole duration to 100% systole duration as indicated by the 
arrows. Arrows pointing up indicate proportional behavior and 
arrows pointing down indicate antiproportional behavior of the 
cardiac function parameter with respect to the control variable 
Table 1.  Hemodynamic Parameters Before and After Device 
Implantation as well as After Induction of Heart Failure  
 
Normal Heart  
Without Implant
Normal Heart 
With Implant Heart Failure
SV (ml) (PAC) 67 (59–79) 72 (65–76) 54 (43–59)
EF (%) (PAC) 41 (39–45) 40 (37–50) 27 (17–37)
HR (bpm) 103 (92–110)* 78 (74–94) 63 (62–80)
MAP (mm Hg) 100 (87–116) 92 (77–103) 61 (50–68)
SvO2 (%) (BGA) 77 (72–81) 74 (65–77) 56 (48–62)
EDV (ml) (PAC) 163 (145–192) 170 (143–204) 198 (160–278)
Data are presented as median (interquartile range). Differences 
of Normal heart with implant to Normal heart without implant were 
analyzed using a paired t test. Presented SV, EF, and EDV values are 
right ventricular.
*p value lower than 0.05 versus Normal heart without implant.
BGA, mixed venous blood gas analysis; EDV, end-diastolic vol-
ume; EF, ejection fraction; HR, heart rate; MAP, mean arterial pres-
sure; PAC, pulmonary artery catheter; SV, stroke volume; SvO2, 
mixed venous oxygen saturation.
Figure 5. Variation of support duration in a stepwise manner to provide optimized cardiac augmentation within the individual electrome-
chanical window; support end at 90% (A), 100% (B), and 110% (C) systole duration is indicated by the arrow and results in an immediate 
drop of left ventricular (LV) pressure. ECG, electrocardiogram. 
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Unrestricted LV function, especially end-diastolic filling, was 
preserved. In addition, CT images revealed no signs of com-
promised ventricular filling (Figure 7A).
Changes of cardiac function parameters with respect to sup-
port duration tSD and support pressures PLV and PRV in the func-
tional HF state are shown in Figures 5 and 6. Figure 5A shows 
an early stop of support (arrow at 90% systole length) during 
systole, which causes an immediate drop in LV pressure. In 
Figure 5B, support duration was set to the length of the systole 
(100%), resulting in an undisturbed morphology of the ventric-
ular pressure curve. Prolonging the support duration towards 
the early diastolic filling phase (110%) as shown in Figure 5C 
leads to an extended isovolumetric relaxation period.
Changes in LVEDP, LVESP, and LVSV during BiVAD, LVAD, 
and isolated RV (RVAD) support for different support pressures 
are shown in Figure 6A. All values were calculated as differ-
ences to their individual baseline without support. All support 
modes elevated LVESP and LVSV proportional to the increasing 
support pressure. However, although BiVAD and LVAD sup-
port decreased LVEDP, it was increased during RVAD support. 
The LV pressure curves during BiVAD support are shown in 
Figure 6B.
Figure 6C summarizes the results of the statistical analysis 
of the complete data set. Statistically significant dependencies 
with p < 0.05 were found with increasing LV or RV support 
pressures and when prolonging support duration from 80% 
systole duration to 100% systole duration as indicated by the 
arrows. Arrows pointing up indicate proportional behavior and 
arrows pointing down indicate antiproportional behavior of the 
cardiac function parameter with respect to the control variable 
(see Table, Supplemental Digital Content, http://links.lww.
com/ASAIO/A187). Statistical significance was not reached 
for the dependency of LVESP on support duration and for the 
dependency of LVSV on RV support pressure, although the bot-
tom right graph of Figure 6A might suggest otherwise.
In Vivo Device Imaging
The effects of BiVAD, LVAD and RVAD support are shown for 
the end-systolic and end-diastolic phase in Figure 7A and supple-
mental video 1 (see Video, Supplemental Digital Content, http://
links.lww.com/ASAIO/A185). In vivo imaging also confirmed the 
importance for individualizing implant design in order to respect 
their fit and their positioning according to the major blood ves-
sels. Figure 7B shows close proximity of the upper rim of the 
implant to the pulmonary veins and the inferior vena cava, both 
of which might otherwise be easily compromised by implant.
Changes in LVSV by means of CT volumetry during BiVAD 
support were 4.1 (4.0–4.3) ml for PLV = 40 mm Hg and 5.7 
(4.9–6.5) ml for PLV = 60 mm Hg and lie within the interquartile 
range of the PiCCO-based measurements shown in Figure 6A. 
EF of the RV and LV in both BiVAD and LVAD mode showed an 
increase, indicating biventricular support (Figure 7C). RVAD 
support did not have significant effects on EF.
BiVAD Support During Cardiac Arrest
We performed 30 min of BiVAD support at 120 bpm with 
LV support pressure of 100 mm Hg and RV support pressure 
of 20 mm Hg after induction of asystole by potassium chloride 
and pentobarbitone overdose. The device was able to main-
tain a CO of 2.5 (2.4–2.8) L/min at a mean arterial pressure of 
35 (34–36) mm Hg (Figure 8A). In some animals, spontaneous 
return of a physiologic ECG signal as an indication of myocar-
dial perfusion occurred. Note the contrast agent distribution in 
the LV and aorta versus the RV (Figure 8, B and C), providing 
evidence for systemic perfusion because it had been injected 
through the central venous line during cardiac arrest. RVEF 
and LVEF measured by CT volumetry were 16% (11%–21%) 
and 22% (20%–27%), respectively.
Discussion
This is the first study to show in vivo observations of a truly 
customized biventricular epicardial augmentation technology 
with regards to both anatomic and functional characteristics. 
The development of the biventricular epicardial augmenta-
tion system described here respects information and findings 
from excellent previous work on direct cardiac compression 
Figure 6. A: Hemodynamic changes from baseline are shown for biventricular assist device (BiVAD), left ventricular assist device (LVAD), 
and right ventricular assist device (RVAD) support in the functional heart failure cardiac state. Boxplots show median, interquartile range, and 
min/max values of left ventricular (LV) end-diastolic pressure (LVEDP), end-systolic pressure (LVESP), and stroke volume (LVSV). B: Pressure 
curves for baseline and during biventricular support (LV unit pressure in mm Hg as indicated, RV unit pressure is 20 mm Hg in all cases). C: 
Results of the statistical analysis: Arrows indicate significant proportional or antiproportional dependency of the respective cardiac function 
parameter on the control variables. 
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devices. Our technology provides various novel solutions 
for the critical aspects, which in their combination results in 
excellent functionality of the system introduced here. This 
includes customized shape by segmentation of imaging data 
for optimal fit and exact positioning to address precise epicar-
dial attachment and to avoid diastolic restriction. In addition, 
individually adjustable LV and RV support using three sepa-
rate pneumatic units to provide biventricular support. More-
over, the development of an ECG-based control algorithm to 
account for synchronized mechanical support within each 
R- to T-wave interval allows to respect intra- and interindivid-
ual differences in systolic and diastolic duration in real time, 
and a self-expandable implant allows the reduction of proce-
dural complexity and invasiveness, which may contribute to 
fast recovery and reduced complications.
The results show that the customized implants provided 
unconstrained cardiac function and no arrhythmias once they 
had been in place. This is an important observation as Mau 
et al. stated that “heart surrounding configuration … is likely 
to constrain ventricular filling and impair early diastolic relax-
ation.”7 In fact, our results showed a trend toward a decrease in 
time constants of the PV loops dp/dtmin and τ during mechani-
cal support (see Figure, Supplemental Digital Content, http://
links.lww.com/ASAIO/A186). Customization also enabled cor-
rect positioning of the implants in a minimally invasive proce-
dure on the beating heart, ensuring correct positioning of the 
pneumatic units in their predefined locations. In this regard, 
we did not observe any signs of mitral regurgitation under 
epicardial augmentation in this model. However, in human 
HF patients with dilated ventricles, the device’s mechanism of 
support may alter the state of already existing functional mitral 
valve regurgitation of varying degrees. Patient-specific design 
and positioning of the augmentation units using 3D imaging 
data analysis may be even useful in this context, particularly 
in case of posterior leaflet restriction. However, this remains 
to be studied.
Support pressures in the subsystemic range of 20–80 mm Hg 
gradually improved cardiac functional parameters in the acute 
failing heart model as indicated by increased SV and ESP, as 
well changes in RVEF and LVEF. This is comparable to what 
has been reported by other groups.12 Importantly, this was only 
observed when ECG-based synchronization of support accord-
ing to each cardiac cycle was optimized.
In contrast to current LVADs, this technology gradually 
increases SV and improves ventricular pressures without cir-
cumvention of the heart. For several reasons, this may be ben-
eficial: it avoids blood contact, thereby, reducing the risk for 
complications, such as bleeding and stroke; applying direct 
pulsatile pressure to the dilated myocardial tissue reduces oxy-
gen consumption and improves cardiac efficiency as recently 
shown in an ovine model of cardiomyoplasty.13 Moreover, pul-
satile support was shown to be superior to continuous flow 
with regard to myocardial recovery in humans.14 The possibility 
to adjust the support to the amount that is individually required 
may be of interest in various ways: it opens room for novel 
individualized treatment and weaning protocols targeting the 
Figure 7. Postimplant computed tomography (CT) images. The effects of biventricular assist device (BiVAD), left ventricular (LV) assist 
device (LVAD) and right ventricular (RV) assist device (RVAD) support are shown in the end-diastolic and end-systolic phase. # indicates RV 
unit, * indicates LV units (A). In (B), the device fit is shown in sagittal view. A three-dimensional (3D) volume rendering shows the importance 
of the anatomic correct positioning of the device with regards to the major vessels. C: Ejection fraction (EF) from left and right ventricular CT 
volumetry. IVC, inferior vena cava; PV, pulmonary vein. 
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reverse remodeling potential of the heart. In addition, it shifts 
mechanical support to a nonobligatory device technology, 
which improves patient safety in situations of malfunction.
Another major observation in the current study is that the 
improvement of hemodynamic parameters is mediated only in 
the context of optimized synchronization of deflation to the 
isovolumetric relaxation phase. As shown, deflation of the 
pneumatic units immediately resulted in a ventricular pressure 
drop. During systole, this stopped the ejection of blood from 
the ventricles because the ventricular pressure had dropped 
below the augmented aortic/pulmonary arterial pressure. Sta-
tistical analysis of the data clearly indicated that with similar 
support pressures, shortened support duration leads to a reduc-
tion in LVSV and an increase in LVEDP when compared with 
optimal timing. Further prolongation of support may have an 
influence on diastolic filling over time, in particular in cases 
of higher HRs, and needs to be explored in more detail. This is 
an important finding not reported in this detail in the literature 
so far. It suggests that an adaptive, dynamic synchronization 
algorithm is mandatory for sustained epicardial mechanical 
support, particularly in the low-pressure range. It also indi-
cates that improvement of ventricular function by epicardial 
augmentation is multifactorial, consisting of concise systolic 
inflation of augmentation units in predefined locations, timed 
diastolic deflation, and unrestricted diastolic filling. The latter 
may be of particular importance as McGarvey et al. observed 
velocity profiles that indicated the most notable effect on blood 
velocity was seen during diastolic deflation in pigs.15
In the current study, the device was used in both uni- and 
biventricular support modes. As shown, epicardial augmenta-
tion with subsystemic augmentation pressures in BiVAD mode 
and in LVAD mode increased EF from baseline in both ven-
tricles (Figure 7C). Epicardial augmentation with 40 mm Hg 
of pressure in RVAD mode did not have significant effects on 
volumetric EF of both ventricles, but an increase in LVSV was 
observed. This biventricular effect may be explained by two 
geometrical effects of the support units during systolic infla-
tion. First, direct effects on the myocardial region where pres-
sure is applied, and second, a circumferential effect caused by 
the 3D changes during inflation of two or three support units. 
This observation is supported by Mau et al.,7 who reported 
that cavity volume reduction was achieved because the sep-
tal–lateral short-axis change exceeded the anterior–posterior 
lengthening.
This is of particular importance because it is known that in 
patients with single LV failure, the right heart is deteriorating 
under mid-term to long-term support with current LVAD tech-
nology. Moreover, it is known that late-onset RV dysfunction is 
a complication of LVAD therapy, which has significant adverse 
implications with regard to patient outcome.16 Although RV 
Figure 8. The functionality of the device demonstrated after cardiac arrest. The device is thereby triggered by an electrocardiogram (ECG) 
simulator. Left ventricular (LV) and support pressure curves (A), as well as end-diastolic and end-systolic computer tomography (CT) images 
with contrast agent distribution are shown (B and C). PV, pulmonary vein; RV, right ventricle; 
Copyright © American Society of Artificial Internal Organs. Unauthorized reproduction of this article is prohibited.
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function under epicardial support was already investigated in a 
previous study,7 the long-term effects with regards to the func-
tional state of the RV remain to be investigated.
Another important finding is the use of a fixed frequency 
support in situations of cardiac arrest over periods greater 
than 30 min. It allowed extended biventricular hemodynamic 
support and may be suitable for patients at risk. As shown in 
 Figure 8, the functionality of this mode allows systemic per-
fusion with CO of around 2.5l∙/min in this pig model. Even 
though resuscitation may not be the primary focus of this 
device, it clearly shows the effectiveness of this biventricu-
lar epicardial augmentation device regarding systemic perfu-
sion. In the context of the development of clinical product for 
human use, its safety in terms of correct interpretation of the 
individual’s ECG needs further exploration.
In conclusion, the present evaluation provides evidence that 
the use of a novel biventricular epicardial augmentation tech-
nology—by customized configuration and stable implant posi-
tioning, as well as synchronized timing of mechanical support 
according to each cardiac cycle—leads to improved hemody-
namic parameters and might, thereby, beneficially modulate 
cardiac energy consumption. The fulfillment of these prerequi-
sites was made possible by technical improvements in image 
processing, real-time signal analysis with modern electronic 
hardware, and algorithms.
The implantation and positioning on the beating heart 
appears safe and can be performed without sternotomy or the 
use of cardiopulmonary bypass. In addition, no anastomosis 
of foreign material to major blood vessels or the LV is neces-
sary. This less-invasive procedure, thereby, reduces complexity 
and trauma to the patient, and its use may reduce complica-
tions associated with anticoagulation, including stroke and 
bleeding.
Finally, in the acute setting, we did not observe any del-
eterious injuries to the heart or large vessels during implan-
tation and support. Based on our experience, the device is 
currently developed into a product system aiming at CE Mark 
and intended to be used in humans. There is a clear need for 
less invasive, biventricular devices that avoid blood contact for 
mechanical assistance of patients with advanced HF. With this 
device augmentation, pressures and volumes may be adjusted 
to meet the requirements of each individual patient. Thereby, 
it may be used earlier during the course of the disease process 
to bridge patients to transplantation. Because the technology 
avoids contact with the blood, it may reduce complications, 
including bleeding and stroke in patients at risk. One major 
aspect for long-term use of this technology in patients not hav-
ing an option for transplantation is durability. This will be fur-
ther optimized and tested, but clearly, one major goal is the 
development of a long-term device as an alternative to heart 
transplantation, which is limited by organ donor shortage.
Study Limitations
In this study, the drug-induced HF model used was only in 
part able to mimic the hemodynamic state of a failing heart. In 
addition, the geometry and mechanical structure of the hearts 
were normal. Even though we were able to test the device’s 
functionality, this is clearly a limitation. The functionality of the 
implant is expected to be more efficient when used in hearts that 
underwent remodeling to a dilated, thin-walled morphology. It 
has been suggested previously that hemodynamic augmenta-
tion should be much more efficient during the latter condition.17
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